Antibody Ingredients TRIZ Cases

FcγR-dependent crosslinking can limit anti-CD27 potency and trigger unwanted effector functions; modified Fc regions enable IgG hexamer-driven activation.

Dual TIM-3 and PD-1 checkpoint blockade addresses poor outcomes in aggressive tumors by strengthening the anti-tumor effect.

Host-cell esterase can degrade polysorbate surfactants; removing that activity helps limit subvisible particles in protein formulations.

BTLA agonist antibodies target coinhibitory signaling in autoreactive T and B cells, reducing autoimmune activity while preserving broader immune function.

Defined ALK2/ALK3 antibody dosing targets activin A receptor signaling to address bone loss while limiting treatment side effects.

Replacing mouse framework regions with human sequences preserves nanomolar PSMA affinity while reducing the adverse immune response.

A DLL3–CD3 heteromultimer bridges tumor cells and T cells to support targeted killing in chemoresistant neuroendocrine cancers.

Co-administer hydroxyprogesterone caproate with lenvatinib or anti-PD-1/PD-L1 antibodies to counter immune escape and improve immunotherapy efficacy.

Anti-CTLA-4 antibodies address modest treatment efficacy in non-MSI-H/dMMR metastatic colorectal cancer by activating T cells and reducing tumor burden.

Combining HVEM-pathway and HSP inhibitors targets complementary cancer mechanisms, producing synergistic anticancer activity within 72 hours.

A CAPRIN-1 antibody paired with a MEK, RAS, RAF, or ERK inhibitor strengthens antitumor action and addresses resistance.

ROR1 antibodies and vaccines bind its Ig-like domain to reduce cancer-cell migration and metastatic potential.

Recombinant antibodies targeting DDX53, KIF3C, and AKR1A1 address limited treatment options for melanoma with leptomeningeal spread.

An Fc-binding intermediary directs site-specific payload transfer to antibodies, improving structural homogeneity and preserving antibody function.

CD39-targeted antibodies use ADCC and ADCP to deplete eosinophils, reduce inflammation, and limit systemic adverse effects.

See how anti-Notch3 antibodies block Jag1, Jag2, DLL1, and DLL4 binding to inhibit signaling and tumor cell proliferation.

Specific CDR sequences and protease-cleavable linkers support selective FAP binding, internalization, and tumor-cell killing.

Non-CDR loops mask target binding during circulation, while a cleavable linker enables tumor-microenvironment activation and limits non-specific binding.

VHH antibody units target TIGIT independently, simplifying multispecific construction while enhancing immune-cell activity against cancer cells.

Concentration-dependent binding activates anti-CTLA-4 antibodies in adenosine-rich tumors, limiting systemic autoimmune effects.

Humanized anti-Lewis Y antibodies preserve parent-like affinity while avoiding Lewis b binding for more selective cancer therapy.

Specific anti-PD-1 antibody doses and intervals balance T-cell activation with controlled cancer treatment response.

Defined variable regions and CDR sequences enable anti-LAG-3 antibodies to block immune suppression and increase T cell activation.

Click chemistry directs drug attachment to K246/K248 in the Fc region, improving ADC homogeneity while preserving antibody function.

ILT-binding antibodies block inhibitory ILT2 and ILT4 signaling to counter cancer-cell immune evasion and restore antitumor responses.

Antibody-oligonucleotide conjugates target cardiac transferrin receptors to deliver RNAi payloads and reduce PLN expression.

After cytoreduction lowers peripheral cancerous cells, sub-saturating 225Ac-HuM195 targets CD33 while limiting antibody toxicity.

Affinity maturation and humanization improve NRP2 binding specificity to modulate ligand interactions and downstream signaling.

Targeted type I IFN inhibition normalizes GlycA, NET, TNF-α, and IL-10 markers while reducing cardiovascular risk in SLE.

P329R and E345R Fc mutations enhance OX40 antibody agonism while reducing Fc effector functions for antitumor therapy.

Defined CDR sequences improve PSMA antibody affinity and specificity for targeted cancer therapy, addressing limits of existing treatments.

Selective VEGF inhibition with tivozanib addresses refractory renal cell carcinoma after prior therapies while limiting off-target toxicities.

Specific variable-region sequences block CD47–SIRPα signaling, enabling macrophage phagocytosis of tumor cells without erythrocyte agglutination.

Targeted canine IgM μ-chain binders deliver MMAE to B-cell lymphoma cells, aiming to improve cytotoxicity while limiting systemic toxicity.

By targeting iRhom2 upstream of ADAM17, humanized antibodies can reduce TNF-α and other cytokine release where direct inhibitors lacked clinical success.

Fc engineering helps anti-ICOS antibodies stimulate effector T cells while depleting regulatory T cells for stronger tumor control.

CD137-mediated cross-linking gates agonist activity, boosting T-cell function while avoiding the hepatotoxicity of anti-CD137 therapy.

Donor-derived human IgG1 antibodies address limited fungal diagnostics and murine-antibody immunogenicity while supporting Candida detection and therapy.

A bivalent anti-cMPL scFv delivers diphtheria toxin to hematopoietic stem cells for targeted marrow clearance with reduced off-target toxicity.

Combining anti-NKG2A with trastuzumab and checkpoint antibodies helps restore immune recognition after progression in advanced cancers.

By reshaping HHLA2, these agents inhibit KIR3DL3 binding while enhancing TMIGD2 interaction for stronger T-cell and NK-cell responses.

CD32b-targeting antibodies enhance interferon-alpha secretion and restore neutrophil populations to treat viral infection and prevent acute respiratory distress.

Shark VNAR domains target ROR1 with engineered CDRs, addressing antibody size limits and improving penetration into solid tumors.

See how an antibody binding TMPRSS2’s extracellular domain blocks coronavirus entry and maintains inhibition across viral variants.

A caninized antibody blocks canine PD-L1/PD-1 signaling to enhance anti-tumor response in canine cancer models.

Low-affinity CD3 binding helps a BCMA-targeted bispecific antibody recruit T cells while limiting excessive activation and cytokine storm risk.

High-affinity anti-B7H3 antibodies combine internalization and ADCC to inhibit tumor cells while limiting effects on normal tissues.

This case examines multivalent anti-Fn14 Fab and scFv constructs that activate NFκB and enhance TNF-induced cell death without FcγR binding.

This case uses defined antibody CDR sequences to improve NaPi2b binding, cancer-cell internalization, and ADC efficacy.

This case combines CD137 and OX40 binding in one antibody to improve receptor activation while limiting immune-cell depletion.